Aptose Biosciences (APTOF) files 8-K furnishing September 22, 2025 release

Rhea-AI Filing Summary

Aptose Biosciences Inc. filed a current report to furnish information under Regulation FD. On September 22, 2025, the company issued a press release, which is attached to the report as Exhibit 99.1 and incorporated by reference. The company notes that this press release is being furnished under Item 7.01 of the Exchange Act and is not deemed “filed” for liability purposes under Section 18 or automatically incorporated into other securities law filings.

False000088236100008823612025-09-222025-09-22iso4217:USDxbrli:sharesiso4217:USDxbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  September 22, 2025

_______________________________

Aptose Biosciences Inc.

(Exact name of registrant as specified in its charter)

_______________________________

Canada	001-32001	98-1136802
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

66 Wellington Street West, Suite 5300

TD Bank Tower, Box 48

Toronto, Ontario M5K 1E6
Canada

(Address of Principal Executive Offices) (Zip Code)

(647) 479-9828

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

_______________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

On September 22, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Press Release dated September 22, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Aptose Biosciences Inc.
Date: September 22, 2025	By:	/s/ William G. Rice, Ph.D.
		William G. Rice, Ph.D.
		Chairman, President, and Chief Executive Officer

FAQ

What did Aptose Biosciences (APTOF) report in this 8-K filing?

Aptose Biosciences filed a current report to furnish information under Item 7.01 Regulation FD Disclosure, referencing a press release issued on September 22, 2025.

What is Exhibit 99.1 in the Aptose Biosciences 8-K?

Exhibit 99.1 is a press release dated September 22, 2025 that Aptose Biosciences issued and furnished with the current report.

How is the Aptose Biosciences September 22, 2025 press release treated legally?

The press release furnished as Exhibit 99.1 is provided under Item 7.01 and is expressly stated not to be deemed “filed” for purposes of Section 18 of the Exchange Act.

Does this Aptose Biosciences 8-K incorporate the press release into other SEC filings?

The company states the press release is not deemed incorporated by reference into Securities Act or Exchange Act filings, except where specifically referenced in a future filing.

Who signed the Aptose Biosciences September 22, 2025 8-K?

The report was signed on behalf of Aptose Biosciences Inc. by William G. Rice, Ph.D., the company’s Chairman, President, and Chief Executive Officer.

Are there financial statements included in this Aptose Biosciences 8-K?

Under Item 9.01, the company lists only exhibits, including the press release as Exhibit 99.1 and the cover page interactive data file as Exhibit 104.